Skip to main content Help with accessibility Skip to main navigation

Adalimumab

Indication

Crohn's disease, 2nd line biologic (NICE TA187) and LSCMMG Recommendation

NICE TA187 - Infliximab and adalimumab for the treatment of Crohn's Disease

Red

Brand:

Humira®

Nice TA:

187

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Gastro-intestinal system

Background

In CD patients who experience intolerance, secondary failure or primary failure with a first TNF-alpha inhibitor used in line with NICE, treatment with a second NICE TA187-approved TNF-alpha inhibitor may be tried. There is consistent evidence that a second TNF-alpha inhibitor can induce and maintain clinical response and remission in many patients who experience inadequate control or intolerance on their first TNF-alpha inhibitor. Response and remission rates with a second TNF-alpha inhibitor are highest in those who discontinue their first TNF-alpha inhibitor due to intolerance or loss of response, compared with those who discontinue due to lack of an adequate initial response.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Decisions of Lancashire local decision making groups

Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 01 - May - 2016